Spinal Muscular Atrophy (SMA) Preimplantation Genetic Screening for IVF in Hong Kong – Answers
Patients or carriers of Spinal Muscular Atrophy (SMA) can undergo PGT-M for embryo genetic screening when pursuing IVF in Hong Kong. SMN1 gene testing and family pedigree mapping must be completed first before entering the IVF cycle. Some Hong Kong fertility centers have single-gene embryo screening capabilities, but genetic, fertility, and regulatory conditions must be met.
===== Opening: Real Consultation Scenario =====
Ms. Zhou and her husband are both carriers of Spinal Muscular Atrophy (SMA). Their previous child was diagnosed with SMA type I and passed away due to respiratory failure at 6 months of age. Their genetic counseling report shows that both have a homozygous deletion of exon 7 in the SMN1 gene, placing their family at high genetic risk for SMA. Ms. Zhou is 33 years old, with an AMH of 1.8 ng/mL, indicating acceptable ovarian reserve. She wants to know: Can embryos be screened for SMA when undergoing IVF in Hong Kong?
===== Module A: Direct Answer to the Question =====
Can embryos be screened for SMA during IVF in Hong Kong?
Yes. Some fertility centers in Hong Kong holding a Human Reproductive Technology Licence possess the technical capability for PGT-M (Preimplantation Genetic Testing for Monogenic Disorders) and can perform embryo genetic screening for Spinal Muscular Atrophy. However, the implementation of this technology requires meeting all of the following conditions:
- Genetic Condition: The SMN1 gene mutation type of the proband or both parents must be clearly identified, and sufficient samples (proband DNA, parental peripheral blood) must be available to establish a single-gene testing protocol and linkage analysis.
- Fertility Condition: The female partner’s ovarian function (AMH, antral follicle count) must be sufficient to obtain an adequate number of eggs, with an expectation of forming at least 6–8 blastocysts for biopsy and selection.
- Regulatory Condition: Must comply with the regulatory requirements of the Hong Kong Human Reproductive Technology Ordinance for embryo genetic testing. The receiving hospital must have PGT qualifications and genetic laboratory support.
All three conditions are essential. If genetic information is incomplete or ovarian reserve is too low, the feasibility of PGT-M will be significantly reduced.
===== Module B: Why This Question Arises =====
Why do SMA families need PGT-M screening?
Spinal Muscular Atrophy is an autosomal recessive genetic disorder caused by mutations in the SMN1 gene (5q13.2). Carriers themselves do not develop the disease, but if both partners are carriers, each pregnancy has a 25% chance of having an affected child, a 50% chance of an asymptomatic carrier, and a 25% chance of a completely unaffected child. Routine prenatal screening (NIPT) cannot detect single-gene disorders, and amniocentesis can only be performed after 16 weeks of gestation, involving physical and emotional trauma if termination is considered.
PGT-M advances genetic diagnosis to before embryo transfer. By detecting the SMN1 gene copy number in blastocysts, it selects embryos without the pathogenic mutation for transfer, thus preventing the transmission of SMA at its source. For families who have previously had a child with SMA or have a clear family history, this is currently the most effective assisted reproductive strategy for genetic prevention.
===== Module I: Actual Process =====
Actual process of SMA embryo screening
From genetic counseling to completing the transfer, the process typically includes the following 8 steps:
| Stage | Core Content |
|---|---|
| 1 Genetic Counseling | Confirm SMA mutation type (SMN1 deletion/point mutation), construct family pedigree, assess genetic risk and PGT-M indications. |
| 2 Genetic Testing | SMN1 gene testing of the proband (or both parents), SMN2 copy number analysis if necessary, establish a single-gene diagnostic protocol. |
| 3 Center Selection | Confirm that the Hong Kong fertility center has PGT-M qualifications and a single-gene testing laboratory, and agrees to accept cross-border cases. |
| 4 IVF Cycle | Ovarian stimulation (8–14 days), egg retrieval, in vitro fertilization, blastocyst culture (days 5–6). |
| 5 Embryo Biopsy | Biopsy 5–10 cells from the trophectoderm, without damaging the inner cell mass. |
| 6 Genetic Testing | Whole genome amplification of biopsied cells, SMN1 gene copy number detection + linkage analysis (to reduce ADO errors). |
| 7 Embryo Selection | Select blastocysts that are unaffected and chromosomally normal, record diagnostic results. |
| 8 Frozen Embryo Transfer | Prepare the endometrium (natural cycle or hormone replacement cycle), thaw and transfer selected healthy embryos. |
Throughout the process, the genetic testing steps (steps 2 and 6) are critical to the success of PGT-M and require the involvement of an experienced genetic laboratory.
===== Module J: Timeline =====
Screening and treatment timeline
From initiating genetic counseling to completing embryo transfer, a full cycle typically takes 3–6 months, depending on the speed of genetic testing, the female partner’s ovarian response, and the laboratory schedule. The following is a phase-by-phase time reference:
| Phase | Estimated Duration |
|---|---|
| Genetic counseling + family testing | 2–4 weeks |
| PGT-M protocol development (including linkage analysis design) | 4–8 weeks (requires proband sample) |
| Ovarian stimulation + egg retrieval + blastocyst culture | 3–4 weeks |
| Embryo biopsy + genetic testing | 2–4 weeks |
| Frozen embryo transfer cycle (endometrial preparation) | 4–6 weeks |
| Total | Approximately 14–26 weeks (3–6 months) |
If multiple ovarian stimulation cycles are needed to accumulate embryos, the total time will be extended accordingly. It is advisable to plan ahead to avoid delays due to tests or documentation issues.
===== Module G: Most Easily Overlooked Details =====
Four key details most easily overlooked
- Differences in PGT-M qualifications: Not all Hong Kong fertility centers hold a licence for single-gene testing. Some centers can only perform PGT-A (chromosomal aneuploidy screening) and lack the capability for SMN1 gene testing. Before choosing a center, verify whether the laboratory has single-gene diagnostic qualifications.
- Family samples are indispensable: PGT-M requires DNA samples from the proband (affected family member) or both parents to establish a linkage analysis protocol. If the proband has passed away and no sample was preserved, it may be impossible to distinguish between carrier and unaffected embryos, reducing screening accuracy to below 90%.
- Allele drop-out (ADO) risk: During PCR amplification, one allele may not be amplified, leading to misdiagnosis. Standard laboratories simultaneously use linkage analysis (STR or SNP) as an internal control to keep the ADO misdiagnosis rate below 1–2%.
- Differences between Hong Kong regulations and mainland China: Hong Kong has clear licensing management and indication requirements for PGT, and some genetic diseases require ethical approval. Additionally, Hong Kong currently has strict restrictions on non-medical sex selection. SMA screening, being a medical indication, is not affected.
===== Module Q: Frequently Asked Questions =====
Frequently asked questions
===== Module C: Doctor’s Perspective =====
Reproductive medicine perspective: Indications and boundaries of SMA screening
From the clinical value of genetic prevention, PGT-M is currently the most effective upstream intervention for families at high genetic risk for SMA. However, in clinical practice, doctors strictly evaluate two aspects:
- Genetic completeness: If the proband sample is missing or the mutation type is unclear, the misdiagnosis rate of PGT-M increases significantly. The doctor may recommend postponing or using prenatal diagnosis as an alternative.
- Fertility efficiency: A PGT-M cycle consumes embryos. For individuals with low ovarian reserve, there is a risk of having no embryos available for transfer. The doctor will consider AMH, age, and previous ovarian stimulation history to calculate the expected number of eggs and biopsiable blastocysts, and determine the practical feasibility of PGT-M.
Doctors do not recommend PGT-M for all SMA carriers. For younger women (<35 years) with normal ovarian function and clear family genetic information, the advantages of PGT-M are most pronounced. For older women (≥40 years) or those with significantly diminished ovarian reserve, the doctor may suggest first attempting conventional IVF to accumulate embryos before PGT-M, or directly discuss the prenatal diagnosis pathway.
===== Module R: Practitioner Observations =====
Practitioner observation: Most common obstacles in SMA genetic prevention
In the practical work of SMA genetic prevention, the biggest bottleneck is not the technology, but the completeness of genetic information. Many families, after having an affected child, fail to preserve the proband’s DNA sample (blood or tissue block) in time. This prevents the establishment of a linkage analysis protocol for subsequent PGT-M, forcing reliance solely on SMN1 copy number detection, which reduces the accuracy of distinguishing carriers from unaffected embryos from 98% to 85–90%.
Another common issue is insufficient understanding of Hong Kong regulations and center qualifications. Some families travel to a center without first confirming whether it has single-gene testing qualifications, only to be told upon arrival that PGT-M cannot be performed, wasting time and money.
Therefore, it is recommended that families with a history of SMA or known carrier status complete genetic counseling as early as possible before planning a pregnancy, and preserve the DNA sample of the proband (if any). Before choosing a Hong Kong center, verify whether the institution holds a PGT-M licence and request data on its diagnostic accuracy for previous single-gene tests.
===== Closing: Risk Reminder =====
— This article is based on consensus in assisted reproductive medicine and the regulatory framework of the Hong Kong Human Reproductive Technology Authority. It does not constitute medical advice. Please refer to clinical genetic counseling for specific situations.
0 comments